The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 22, 2016
Filed:
Jun. 03, 2015
Applicant:
Celgene Corporation, Summit, NJ (US);
Inventor:
Jerome B. Zeldis, Princeton, NJ (US);
Assignee:
Celgene Corporation, Summit, NJ (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/454 (2006.01); A61K 31/00 (2006.01); A61K 31/40 (2006.01); A61K 31/425 (2006.01); A61K 31/445 (2006.01); A61K 31/515 (2006.01); A61K 31/7076 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/454 (2013.01); A61K 31/00 (2013.01); A61K 31/40 (2013.01); A61K 31/425 (2013.01); A61K 31/445 (2013.01); A61K 31/515 (2013.01); A61K 31/7076 (2013.01); A61K 39/3955 (2013.01); A61K 39/39541 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01);
Abstract
Methods of treating, preventing or managing leukemias are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed.